Dual agonists produce more weight loss on average in clinical trials, making them objectively more effective for total weight loss
This is an Open Access article licensed under a Creative Commons Attribution 4.0 International License ( which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made
The role of trust in diabetes care is emblematic of the progress made in medication delivery systems, reflecting a trend towards treatments that not only improve health outcomes but also enhance the patient experience
Semaglutide vs Tirzepatide: Side-by-Side Comparison The most important takeaway is that semaglutide vs tirzepatide is not only a question of which medication is stronger
The most commonly reported adverse effects are gastrointestinal in nature , affecting a significant proportion of patients, particularly during the initial weeks of treatment or following dose escalation
The overall heterogeneity levels were 24.4% (95% uncertainty intervals, 0 and 54.9%) for nonfatal MI (moderate), 11.1% (95% uncertainty intervals, 0 and 48.0%) for nonfatal stroke (low) and 15.8% (95% uncertainty intervals, 0 and 49.9%) for CV death (moderate) (Additional file 1: Table S3)